Loading news...
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty-seven ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have given a buy rating to the
Alnylam Pharmaceuticals (NASDAQ: ALNY) used its presentation at the JPMorgan Healthcare Conference to outline what CEO Yvonne Greenstreet called the company's "next exciting chapter," highlighting a breakout commercial year in 2025, new long-term targets through 2030, and a pipeline that management said is designed to extend its leadership in RNA interference (RNAi) therapeutics. 2025 performance and
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) announced a new five-year roadmap, "Alnylam 2030," on Sunday, outlining the company's focus on scaling its operations.
Nisa Investment Advisors LLC grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 47.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,133 shares of the biopharmaceutical company's stock after buying an additional 3,891 shares during the period.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, “Alnylam 2030,” focused on scaling the Company's operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility. Alnylam also today reported preliminary* fourth quarter and full year 2025 global net product.
Cerity Partners LLC boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 171.2% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 27,429 shares of the biopharmaceutical company's stock after acquiring an additional 17,316 shares during the quarter. Cerity Partners
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:00 am PT (12:00 pm ET) at The Westin St. Francis in San Francisco. During the presentation, the Company will unveil its new five-year strategy, which will guide the Company's next phase of gro.
Generali Asset Management SPA SGR increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 6,368.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,234 shares of the biopharmaceutical company's stock after buying an additional 3,184 shares during the quarter. Generali
Merit Financial Group LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 123.9% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,231 shares of the biopharmaceutical company's stock after purchasing an additional 2,341 shares during the quarter.
Osaic Holdings Inc. boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 132.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,787 shares of the biopharmaceutical company's stock after acquiring an additional 2,158 shares during the quarter. Osaic Holdings Inc.'s
Vertiv Holdings Co. is expected to be next in line to join the S&P 500 during the first quarter of 2026, according to prediction markets.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-eight research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and twenty-three have assigned a buy recommendation to
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Assenagon Asset Management S.A. increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 354.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 80,381 shares of the biopharmaceutical company's stock after acquiring an additional 62,695 shares during the period.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing to invest $250 million to advance what is poised to become the industry's first fully dedicated, proprietary, siRNA enzymatic-ligation manufacturing facility. This investment is expected to meaningfully expand capacity, significantly reduce pr.
Alnylam (NASDAQ: ALNY) has corrected by roughly 13% over the past couple of weeks. To understand why this pullback is unfolding now, it is important to examine the stock's structure through the lens of the Adhishthana principles and assess where it stands within its broader cycle.
The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, effective December 22, 2025.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with certain holders of its 1.00% Convertible Senior Notes due 2027 (the “Notes”) to repurchase for cash (the “Repurchases”) approximately $34.4 million aggregate principal amount of the Notes for a total repurchase cost (including accrued and unpaid interest) of approxima.
Federated Hermes Inc. increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 22.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 323,842 shares of the biopharmaceutical company's stock after acquiring an additional 59,669 shares during the period.